Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rigel Pharmaceuticals (Nasdaq: RIGL), a commercial stage biotechnology company specializing in hematologic disorders and cancer treatments, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's president and CEO, Raul Rodriguez, will deliver a company overview on Thursday, January 16, 2025, at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco.
The presentation will be accessible via live webcast through the Investor Relations section of Rigel's website. Founded in 1996 and headquartered in South San Francisco, California, Rigel focuses on discovering, developing, and providing innovative therapies for patients with hematologic disorders and cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL), una compagnia di biotecnologia in fase commerciale specializzata in disturbi ematologici e trattamenti per il cancro, ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan. Il presidente e CEO dell'azienda, Raul Rodriguez, presenterà una panoramica dell'azienda giovedì 16 gennaio 2025, alle 8:15 ora del Pacifico (11:15 ora orientale) a San Francisco.
La presentazione sarà accessibile tramite webcast in diretta nella sezione Relazioni con gli Investitori del sito web di Rigel. Fondata nel 1996 e con sede a South San Francisco, California, Rigel si concentra sulla scoperta, sviluppo e fornitura di terapie innovative per i pazienti con disturbi ematologici e cancro.
Rigel Pharmaceuticals (Nasdaq: RIGL), una empresa de biotecnología en etapa comercial especializada en trastornos hematológicos y tratamientos contra el cáncer, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan. El presidente y CEO de la compañía, Raul Rodriguez, ofrecerá una visión general de la empresa el jueves 16 de enero de 2025, a las 8:15 a.m. PT (11:15 a.m. ET) en San Francisco.
La presentación estará disponible a través de una retransmisión web en vivo en la sección de Relaciones con Inversores del sitio web de Rigel. Fundada en 1996 y con sede en South San Francisco, California, Rigel se enfoca en descubrir, desarrollar y proporcionar terapias innovadoras para pacientes con trastornos hematológicos y cáncer.
리겔 제약 (Nasdaq: RIGL)은 혈액 질환 및 암 치료를 전문으로 하는 상업 단계의 생명공학 회사로, 제43회 J.P. 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 Raul Rodriguez는 2025년 1월 16일 목요일 오전 8시 15분 PT (오전 11시 15분 ET) 샌프란시스코에서 회사 개요를 발표합니다.
발표는 리겔 웹사이트의 투자자 관계 섹션을 통해 실시간 웹캐스트로 제공될 예정입니다. 1996년에 설립되어 캘리포니아주 샌프란시스코 남부에 본사를 둔 리겔은 혈액 질환 및 암 환자를 위한 혁신적인 치료법을 발견, 개발 및 제공하는 데 주력하고 있습니다.
Rigel Pharmaceuticals (Nasdaq: RIGL), une entreprise de biotechnologie en phase commerciale spécialisée dans les troubles hématologiques et les traitements du cancer, a annoncé sa participation à la 43ème Conférence Annuelle de Santé J.P. Morgan. Le président et PDG de l'entreprise, Raul Rodriguez, présentera un aperçu de l'entreprise le jeudi 16 janvier 2025, à 8h15 PT (11h15 ET) à San Francisco.
La présentation sera accessible en direct via un webcast dans la section Relations Investisseurs du site web de Rigel. Fondée en 1996 et ayant son siège à South San Francisco, en Californie, Rigel se concentre sur la découverte, le développement et la fourniture de thérapies innovantes pour les patients atteints de troubles hématologiques et de cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL), ein biotechnologisches Unternehmen in der kommerziellen Phase, das sich auf hämatologische Erkrankungen und Krebsbehandlungen spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference bekannt gegeben. Der Präsident und CEO des Unternehmens, Raul Rodriguez, wird am Donnerstag, den 16. Januar 2025, um 8:15 Uhr PT (11:15 Uhr ET) in San Francisco einen Überblick über das Unternehmen präsentieren.
Die Präsentation wird über einen Live-Webcast im Bereich Investor Relations der Website von Rigel zugänglich sein. Rigel wurde 1996 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien. Das Unternehmen konzentriert sich darauf, innovative Therapien für Patienten mit hämatologischen Erkrankungen und Krebs zu entdecken, zu entwickeln und bereitzustellen.
- None.
- None.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302345248.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
When is Rigel Pharmaceuticals (RIGL) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors access Rigel's (RIGL) J.P. Morgan Healthcare Conference presentation?
What is Rigel Pharmaceuticals' (RIGL) main business focus?
When was Rigel Pharmaceuticals (RIGL) founded and where is it located?
